{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T06:30:24Z","timestamp":1775025024309,"version":"3.50.1"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Osteoporosis in men is an increasingly recognized health issue associated with reduced bone mineral density (BMD) and elevated fracture risk. While both antiresorptive and anabolic therapies are recommended in clinical practice, evidence directly comparing these drug classes in male populations remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a systematic review and Bayesian network meta-analysis (NMA), registered on PROSPERO (CRD420251151177), to assess the efficacy and safety of pharmacological interventions for male osteoporosis. Randomized controlled trials (RCTs) evaluating alendronate, risedronate, zoledronic acid, denosumab, teriparatide, or abaloparatide were identified from PubMed, Web of Science, and the Cochrane Library through 2025. Primary outcomes included percent change in lumbar spine, femoral neck, and total hip BMD at 12 months. Safety outcomes were all adverse events (AEs) and serious adverse events (SAEs). Category-level meta-analyses were further conducted to compare pooled effects of antiresorptive versus anabolic agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighteen RCTs comprising 19\u20131199 participants each were included. At the drug level, abaloparatide and teriparatide ranked highest for lumbar spine BMD, while alendronate and abaloparatide demonstrated the most favorable effects for femoral neck and total hip BMD, respectively. Safety profiles were broadly similar, with teriparatide and alendronate showing relatively lower risks of AEs and SAEs. At the class level, anabolic therapies significantly outperformed antiresorptives in improving lumbar spine (MD 6.62, 95% CI 5.01\u20138.23 vs. 3.58, 95% CI 2.52\u20134.64) and total hip BMD (3.53, 95% CI 2.18\u20134.89 vs. 1.98, 95% CI \u20131.10\u20135.06), whereas antiresorptives showed modest advantages at the femoral neck (1.66, 95% CI 0.57\u20132.75 vs. 1.43, 95% CI \u20130.03\u20132.86). No significant differences were observed between classes in AEs or SAEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provides the first comprehensive drug- and class-level synthesis of treatments for male osteoporosis. Anabolic agents confer greater efficacy at the lumbar spine and total hip, while antiresorptives may offer modest benefits at the femoral neck. Safety outcomes were comparable across drug classes, suggesting that treatment choice should primarily be guided by efficacy considerations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD420251151177.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1714141","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T04:29:13Z","timestamp":1775017753000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy and safety of antiresorptive and anabolic therapies for male osteoporosis: an updated Bayesian network meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Zhichao","family":"Li","sequence":"first","affiliation":[{"name":"Department of Orthopedics, ShaoWu Municipal Hospital of Fujian Province","place":["Shaowu, Fujian, China"]},{"name":"Fujian Minbei Orthopedic Research Institute","place":["Nanping, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Libao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Fujian Minbei Orthopedic Research Institute","place":["Nanping, Fujian, China"]},{"name":"Department of Orthopedics, Nanping First Hospital Affiliated to Fujian Medical University","place":["Nanping, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changhui","family":"Xue","sequence":"additional","affiliation":[{"name":"Fujian Minbei Orthopedic Research Institute","place":["Nanping, Fujian, China"]},{"name":"Department of Orthopedics, Nanping First Hospital Affiliated to Fujian Medical University","place":["Nanping, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengwu","family":"Lu","sequence":"additional","affiliation":[{"name":"Fujian Minbei Orthopedic Research Institute","place":["Nanping, Fujian, China"]},{"name":"Department of Orthopedics, Nanping First Hospital Affiliated to Fujian Medical University","place":["Nanping, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linfeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Fujian Minbei Orthopedic Research Institute","place":["Nanping, Fujian, China"]},{"name":"Department of Orthopedics, Nanping First Hospital Affiliated to Fujian Medical University","place":["Nanping, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.5114\/pm.2017.68596","article-title":"Osteoporosis in men","volume":"16","author":"Misiorowski","year":"2017","journal-title":"Przeglad menopauzalny = Menopause Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-011-0066-z","article-title":"Male osteoporosis: Epidemiology and the pathogenesis of aging bones","volume":"9","author":"Lambert","year":"2011","journal-title":"Curr Osteoporosis Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-023-06720-y","article-title":"Epidemiology of male osteoporosis in Denmark (1996-2018)","volume":"34","author":"Bruhn","year":"2023","journal-title":"Osteoporosis International: A J Established as Result Cooperation Between Eur Foundation For Osteoporosis Natl Osteoporosis Foundation USA"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s40520-023-02478-9","article-title":"Efficacy of osteoporosis pharmacological treatments in men: A systematic review and meta-analysis","volume":"35","author":"Beaudart","year":"2023","journal-title":"Aging Clin Exp Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2147\/clep.S40966","article-title":"The clinical epidemiology of male osteoporosis: A review of the recent literature","volume":"7","author":"Willson","year":"2015","journal-title":"Clin Epidemiol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/js.2018-00118","article-title":"Osteoanabolic agents for osteoporosis","volume":"2","author":"Haas","year":"2018","journal-title":"J Endocr Soc"},{"key":"B7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11914-008-0005-9","article-title":"Combination anabolic and antiresorptive therapy for osteoporosis: Opening the anabolic window","volume":"6","author":"Bilezikian","year":"2008","journal-title":"Curr Osteoporosis Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13766","article-title":"Osteoanabolic and dual action drugs","volume":"85","author":"Tabacco","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.14668","article-title":"Osteoporosis treatment efficacy for men: A systematic review and meta-analysis","volume":"65","author":"Nayak","year":"2017","journal-title":"J Am Geriatrics Soc"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/259818","article-title":"The evidence for efficacy of osteoporosis treatment in men with primary osteoporosis: A systematic review and meta-analysis of antiresorptive and anabolic treatment in men","volume":"2011","author":"Schwarz","year":"2011","journal-title":"J Osteoporosis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta9220","article-title":"A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis","volume":"9","author":"Stevenson","year":"2005","journal-title":"Health Technol Assess (Winchester England)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s41687-024-00727-7","article-title":"Guideline for reporting systematic reviews of outcome measurement instruments (Omis): Prisma-Cosmin for Omis 2024","volume":"8","author":"Elsman","year":"2024","journal-title":"J Patient-Reported Outcomes"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2012.06.016","article-title":"Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study","volume":"51","author":"Boonen","year":"2012","journal-title":"Bone"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-015-3148-4","article-title":"Efficacy of bisphosphonates against osteoporosis in adult men: A meta-analysis of randomized controlled trials","volume":"26","author":"Chen","year":"2015","journal-title":"Osteoporosis International: A J Established as Result Cooperation Between Eur Foundation For Osteoporosis Natl Osteoporosis Foundation USA"},{"key":"B15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12874-018-0483-0","article-title":"Dealing with missing standard deviation and mean values in meta-analysis of continuous outcomes: A systematic review","volume":"18","author":"Weir","year":"2018","journal-title":"BMC Med Res Methodol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/0962280219889080","article-title":"Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis","volume":"29","author":"McGrath","year":"2020","journal-title":"Stat Methods Med Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.12659\/msm.935491","article-title":"Pharmacological therapies for osteoporosis: A Bayesian network meta-analysis","volume":"28","author":"Shen","year":"2022","journal-title":"Med Sci Monitor: Int Med J Exp Clin Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1186\/s13018-021-02678-x","article-title":"Effect of drugs on bone mineral density in postmenopausal osteoporosis: A Bayesian network meta-analysis","volume":"16","author":"Migliorini","year":"2021","journal-title":"J Orthopaedic Surg Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12874-019-0829-2","article-title":"Bugsnet: An R package to facilitate the conduct and reporting of Bayesian network meta-analyses","volume":"19","author":"B\u00e9liveau","year":"2019","journal-title":"BMC Med Res Methodol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1054","article-title":"Automating network meta-analysis","volume":"3","author":"van Valkenhoef","year":"2012","journal-title":"Res Synth Methods"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2022.08.042","article-title":"Epidemiological, methodological, and statistical characteristics of network meta-analysis in anaesthesia: A systematic review","volume":"130","author":"Sehmbi","year":"2023","journal-title":"Br J Anaesthesia"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-005-0004-4","article-title":"Efficacy of risedronate in men with primary and secondary osteoporosis: Results of a 1-year study","volume":"26","author":"Ringe","year":"2006","journal-title":"Rheumatol Int"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-008-0689-2","article-title":"Sustained efficacy of risedronate in men with primary and secondary osteoporosis: Results of a 2-year study","volume":"29","author":"Ringe","year":"2009","journal-title":"Rheumatol Int"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2011.10.024","article-title":"Bisphosphonates and glucocorticoid osteoporosis in men: Results of a randomized controlled trial comparing zoledronic acid with risedronate","volume":"50","author":"Sambrook","year":"2012","journal-title":"Bone"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1870","article-title":"Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the Eurogiops trial","volume":"28","author":"Gl\u00fcer","year":"2013","journal-title":"J Bone Mineral Research: Off J Am Soc For Bone Mineral Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-4175","article-title":"Clinical trials express: Fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: Denosumab fracture intervention randomized placebo controlled trial (Direct)","volume":"99","author":"Nakamura","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.19260","article-title":"Denosumab for osteoporosis in older adults in long-term care: A randomized trial","volume":"73","author":"Greenspan","year":"2025","journal-title":"J Am Geriatrics Soc"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac486","article-title":"Abaloparatide increases lumbar spine and hip BMD in Japanese patients with osteoporosis: The phase 3 Active-J study","volume":"107","author":"Matsumoto","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4719","article-title":"The efficacy and safety of abaloparatide-sc in men with osteoporosis: A randomized clinical trial","volume":"37","author":"Czerwinski","year":"2022","journal-title":"J Bone Mineral Research: Off J Am Soc For Bone Mineral Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4314\/tjpr.v20i10.26","article-title":"Comparative efficacy and safety of alendronate and teriparatide in bone loss reduction and prevention of vertebral fracture in osteoporotic Chinese patients","volume":"20","author":"Qi","year":"2021","journal-title":"Trop J Pharm Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-012-9819-4","article-title":"Combination therapy with risedronate and teriparatide in male osteoporosis","volume":"44","author":"Walker","year":"2013","journal-title":"Endocrine"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1569","article-title":"A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density","volume":"97","author":"Orwoll","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1204061","article-title":"Fracture risk and zoledronic acid therapy in men with osteoporosis","volume":"367","author":"Boonen","year":"2012","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2011.03666.x","article-title":"Once-yearly zoledronic acid in older men compared with women with recent hip fracture","volume":"59","author":"Boonen","year":"2011","journal-title":"J Am Geriatrics Soc"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.119","article-title":"Efficacy and safety of a once-yearly I.V. infusion of zoledronic acid 5\u2009mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double-blind, active-controlled study","volume":"25","author":"Orwoll","year":"2010","journal-title":"J Bone Mineral Research: Off J Am Soc For Bone Mineral Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-009-0136-9","article-title":"The effects of weekly alendronate therapy in Taiwanese males with osteoporosis","volume":"28","author":"Hwang","year":"2010","journal-title":"J Bone Miner Metab"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.081214","article-title":"Once-weekly risedronate in men with osteoporosis: Results of a 2-year, placebo-controlled, double-blind, multicenter study","volume":"24","author":"Boonen","year":"2009","journal-title":"J Bone Mineral Research: Off J Am Soc For Bone Mineral Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-004-1713-3","article-title":"Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy","volume":"16","author":"Kaufman","year":"2005","journal-title":"Osteoporos Int"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-003-0388-y","article-title":"Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study","volume":"24","author":"Ringe","year":"2004","journal-title":"Rheumatol Int"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200424060-00003","article-title":"Weekly oral alendronic acid in male osteoporosis","volume":"24","author":"Miller","year":"2004","journal-title":"Clin Drug Invest"},{"key":"B42","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis","volume":"18","author":"Orwoll","year":"2003","journal-title":"J Bone Mineral Research: Off J Am Soc For Bone Mineral Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-002-1085-7","article-title":"Alendronate treatment in men with primary osteoporosis: A three-year longitudinal study","volume":"73","author":"Gonnelli","year":"2003","journal-title":"Calcif Tissue Int"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/nejm200008313430902","article-title":"Alendronate for the treatment of osteoporosis in men","volume":"343","author":"Orwoll","year":"2000","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.0747","article-title":"Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial","volume":"175","author":"Greenspan","year":"2015","journal-title":"JAMA Intern Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1714141\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T04:29:16Z","timestamp":1775017756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1714141\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":45,"alternative-id":["10.3389\/fendo.2026.1714141"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1714141","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"article-number":"1714141"}}